A Patient Decision Aid for Patients With Superficial Basal Cell Carcinoma

Status Completed

Clinical Trial Summary

A patient decision aid (PDA) was tested in a population of patients with superficial basal cell carcinoma. This study evaluates whether the use of a PDA improved outcomes like decisional conflict and knowledge.

Clinical Trial Description

Background Patients with a superficial basal cell carcinoma (sBCC) can choose between several treatment options with specific advantages and disadvantages. A patient decision aid (PDA) might facilitate a personalized decision. Objectives This study evaluates whether the use of a PDA results in a decreased level of decisional conflict, improved satisfaction with the treatment decision, and increased knowledge on prevention, recognition of BCC, and treatment options. Methods A prospective multicentre pre- and post-implementation study was performed amongst patients with a newly diagnosed sBCC comparing a group that did not use the PDA (control group) with a group that did (PDA group). The primary outcome was the level of decisional conflict measured by the total mean score on the 'decisional conflict scale' (DCS) directly before treatment. Higher scores correspond with higher levels of decisional conflict (scale 0-100). Knowledge of disease and treatment options was evaluated by using a questionnaire. Results Questionnaires were completed by 103 patients in the control group and 109 patients in the PDA group. The mean total score on the DCS in the control group was 22.78 (SD 14.76) compared to 22.34 (SD 14.54) in the PDA group. The adjusted mean difference was -0.39 (95% CI -4.47-3.70, p=0.851). Cohen's effect size for the total score on the DCS was 0.03. Use of the PDA resulted in a significant increase of knowledge on recognition of BCC (p<0.001) and treatment options for sBCC (p=0.005). According to exploratory subgroup analyses the unadjusted mean difference in DCS score was higher in patients with sBCC in the head and neck area (-4.53, p=0.378), patients without a history of BCC (-3.76, p=0.251), and patients with higher educational level (-4.71, p=0.196). Conclusion In the total study population with newly diagnosed sBCC, use of a PDA increased knowledge on relevant issues, but had no significant effect on the level of decisional conflict when compared with a control group. Exploratory subgroup analyses suggest that specific subgroups of patients may benefit from the use of a PDA, but these results need to be verified in larger studies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05628714
Study type	Observational
Source	Maastricht University Medical Center
Contact
Status	Completed
Phase
Start date	January 1, 2018
Completion date	July 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04552990` - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT03573401` - Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).	Phase 3
Completed	`NCT03012009` - Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial	N/A
Completed	`NCT02270645` - Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser	N/A
Completed	`NCT00469417` - Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma	Phase 3
Recruiting	`NCT05381597` - 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer	Phase 2/Phase 3
Terminated	`NCT00994240` - Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC	N/A
Completed	`NCT00604890` - Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT00189306` - Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream	Phase 3
Recruiting	`NCT05157763` - A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma	Phase 1/Phase 2
Recruiting	`NCT04744935` - Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma	N/A
Completed	`NCT00432185` - To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC	Phase 2
Recruiting	`NCT01491711` - Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate	Phase 4
Completed	`NCT04470726` - Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT01325688` - PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities	Phase 2
Recruiting	`NCT05713760` - Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.